Kolkata, West Bengal -- (SBWIRE) -- 08/29/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS).
It is said that value of Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) is linked to its anti-obesity drug Belviq.
While the firm is not having a pipeline of drugs, its viability is linked to Belviq. This leads to sales figures being monitored closely by long-term investors as well as active traders.
Is ARNA All Set To Bounce Back From New Low And Hit $15? Get Special Report Here
There is potential in the anti-obesity space but it would take a while for it to take some shape. The challenges range from cost to insurance reimbursement as well as acceptance by consumers and consumers.
One needs to look at tracking the drug data for almost 3 to 4 month. Symphony Health tracks sales data. Analysts’ expectations estimate that gross sales would reach $68 million by the end of the year. But, the driver for Arena would be a percentage of net sales. IMS scripts came in at 3,461 in the current week vis-à-vis 3,135 in the previous week, the growth being 10%.
Orexigen may be on the verge of having enough cardiovascular data from Light study on the anti-obesity pill Contrave for a possible resubmission for a new drug application to the FDA by the year end.
The firm would also submit Contrave for European approval. It is one of the three players in the prescription anti-obesity space.
Arena and VIVUS, Inc.(NASDAQ:VVUS) ahave drugs approved by FDA in the market.
While Vivus launched Qsymia last Fall, Arena with marketing partner Eisai, launched Belviq in June. But, Orexigen, may move ahead of it its competitors in Europe.
Has VVUS Reached The Bottom and Ready To Reward Investors? Get Rumors Report Here
The drugs of all the three firms are in development stage but streets have assigned a good rating to them because of the great potential they hold. Arena's Belviq is witnessing a good launch in U.S with sales numbers being decent. The issue lies in hesitancy of insurers to cover anti-obesity medication.
The anti-obesity space still has lot of speculation. There may some price movement in Orexigen over the next few months as applications get submitted in Europe and US.
But, investors should know that approvals take time and that jumping into an investment due to excitement may not be a good move.
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)